{
  "docId": "019de075-60f4-719a-882e-3143e28b60e4",
  "docSlug": "fdbc224a3aaf8eece0f490c97a32599d",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 35 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 35,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide outlines a clinical trial process flow from initial NSCLC 2L+ patient entry through randomization to expansion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-60f4-719a-882e-3143e28b60e4/12",
  "deckHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4",
  "deckJsonHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4.json",
  "deckAnchorHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.94,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "Trial flow diagram showing Part A (Safety) and Part B (Efficacy/Safety/Dose Selection) with randomization into three THIO dosage arms.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62886164-3606-46ed-8926-10024ed98572",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.94,
        "x": 0.03,
        "y": 0.77
      },
      "kind": "list",
      "text": "Primary Endpoints: Safety, ORR, DCR (CR, PR and SD)\nSecondary Endpoints: DoR; PFS; OS\nExploratory Endpoints: PK and PD (activity of THIO in circulating tumor cells measured by specific biomarkers)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e41125e-2306-4bde-8875-4c36f1aebc7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "A Multicenter, Open-Label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with LIBTAYO® (cemiplimab)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28d3e1d8-8613-4b28-83a1-38b8fbabd72f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT05208944?term=05208944&draw=2&rank=1 *Would require FDA agreement",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06204cba-8c09-4cf4-9e2b-08dd164fcfc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "THIO-101 TRIAL: 35 PATIENTS DOSED TO-DATE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06e36c3f-226e-4f73-aa0c-341b75386c92",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "81271b1e-cde1-4711-902b-50265002c0b7",
      "evidence": "Visual representation of trial phases, randomization, and endpoints.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 12,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "b33f6867-01cb-4462-9e1a-0004be744e1a",
      "evidence": "The loop is opened on slide 8 and closed on slide 12, discussing the current state of clinical development and the potential for THIO",
      "position": 1,
      "objective": "Why is now the right time for THIO?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}